BeiGene(BGNE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates • Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and second consecutive quarter of positive non-GAAP operating income • Strengthened franchise leadership in chronic lymphocytic leukemia (CLL) with foundational therapy BRUKINSA, global revenue of $690 million, rapidly progressing pivotal programs for late-stage hematology pipeline • Expanded oncology pipeline with four new mol ...